HELIX, a Double-masked Study of SYL1001 in Patients With Moderate to Severe Dry Eye Disease (DED)
Status:
Completed
Trial end date:
2018-11-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether SYL1001 ophthalmic solution is safe and
effective in the treatment of signs and symptoms of Dry Eye Disease.